Semaglutide: Cost, Uses, Dosage and Side Effects (Ozempic, Wegovy)

Yes, as a prescription medicine sold as Ozempic, Wegovy and Rybelsus; it is not available over the counter. Compounded, counterfeit or "research use only" semaglutide sold directly to consumers is a different, unapproved supply chain. FDA has documented dosing errors, counterfeit product and fraudulent labelling in it.

Ozempic and oral Rybelsus are approved for blood-sugar control in type 2 diabetes. Ozempic is also approved to cut the risk of major cardiovascular events, and of kidney decline and cardiovascular death in chronic kidney disease, in adults with type 2 diabetes. Wegovy is approved for chronic weight management in adults and adolescents with obesity, or overweight plus a weight-related condition, and to cut the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

Semaglutide causes thyroid C-cell tumours in rodents, more with higher doses and longer treatment, at clinically relevant exposures. Whether this happens in humans is unknown. It must not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

The injection starts at 0.25 mg once a week and steps up every 4 weeks, to 0.5 mg, 1 mg and 1.7 mg. For weight management the maintenance dose is 2.4 mg once a week (or 1.7 mg). A prescriber manages this; it is not a number to copy from a forum.

No. FDA has documented dosing errors, counterfeit product, fraudulent labelling and unapproved salt forms in the compounded and grey-market semaglutide supply. A vial labelled "research use only" and sold with dosing instructions is, in FDA's view, being sold for human use outside any approval.

The label says using it with any other GLP-1 receptor agonist, or another semaglutide product, is not recommended. Ask the prescriber managing your care about combining it with anything else.

No. Ozempic is approved only for adults with type 2 diabetes: blood-sugar control and cutting cardiovascular and kidney risk. Semaglutide's weight-management approval is under the brand Wegovy. Prescribing Ozempic for weight loss is legal off-label use, but outside what Ozempic's own label supports with trial data.

Gut effects are by far the most common. On Wegovy, 44% had nausea against 16% on placebo, 30% diarrhoea, 24% vomiting and 24% constipation. The boxed warning covers thyroid C-cell tumours seen in rodents. Less common but serious risks on the label include acute pancreatitis, gallbladder disease, acute kidney injury (postmarketing reports) and worsening diabetic retinopathy in people who already have it.

Don't combine it with another GLP-1 receptor agonist or semaglutide product; the label says this is not recommended. The label also advises against it in severe gastroparesis, and warns that insulin or a sulfonylurea raises the risk of low blood sugar. Never share a pen, even with a new needle, because of infection risk.

Wegovy's label describes long-term treatment, to lose weight and keep it off, and its trials followed patients through 68 weeks. It is ongoing management of a chronic condition, not a short course. A prescriber sets the duration for each person.

No trial data supports that pace. In Wegovy's 68-week trials, weight loss built up gradually to an average of 9.6% to 16.0% of body weight by week 68, against 2.4% to 5.7% on placebo. Individual results vary, and a prescriber can set realistic expectations for you.

No. The trials behind its approval measured total body weight, not fat in any one area. Semaglutide works through appetite and slower stomach emptying, and no medicine can choose where the body loses fat first.

As of 3 October 2026, the lowest Novo Nordisk price is $149 a month for the 1.5 mg Ozempic or Wegovy pill, a starting dose used for the first 30 days. At maintenance doses the pills ($199 to $299) still cost less than the pens ($349 to $499). With commercial insurance that covers it, Novo's savings offers cut the cost to as little as $25 a month. Eligible Medicare Part D members pay $50 a month for Wegovy through the GLP-1 Bridge.

You need a prescription and commercial insurance that covers Ozempic or Wegovy. Novo Nordisk's savings offer then lowers the cost to as little as $25 a month, with at most $100 off each month, so a copay above $125 leaves you paying the copay minus $100. Government beneficiaries, including people on Medicare or Medicaid, are excluded.

At Novo Nordisk's self-pay prices on 3 October 2026, a month of Ozempic costs $349 to $499 for the pen or $149 to $299 for the pill. A month of Wegovy costs $349 to $399 for the pen or $149 to $299 for the pill. New patients pay $199 for their first 2 months of the lowest pen doses. List prices are $1,027.51 a month for Ozempic and $1,349.02 for Wegovy.

At Novo Nordisk's self-pay prices on 3 October 2026, a month of the Ozempic pen costs $349 (0.25 to 1 mg) or $499 (2 mg). A month of the Wegovy pen costs $349 (0.25 to 2.4 mg) or $399 (Wegovy HD 7.2 mg). New patients pay $199 a month for their first 2 months of either pen at 0.25 or 0.5 mg, through 31 December 2026. List prices are $1,027.51 a month for Ozempic and $1,349.02 for Wegovy.

I found no Walmart pharmacy page that prints a semaglutide price. Sam's Club, which Walmart owns, said on 7 January 2026 that its pharmacies would dispense the 1.5 mg Wegovy pill for $149 a month through Novo Nordisk's self-pay offer. TrumpRx.gov lists Novo's self-pay prices as a coupon, which it says retail pharmacies widely accept: $149 to $299 a month for the pills and $199 to $499 for the pens, as of 3 October 2026.

At list price, three pens cost $3,082.53. At Novo Nordisk's self-pay prices on 3 October 2026, three months of the 0.25 to 1 mg pen cost $1,047, and three months of 2 mg cost $1,497. A new patient starting on 0.25 mg pays $199, $199 and then $349, which is $747. With commercial insurance that covers Ozempic, Novo says you may pay as little as $25 for a prescription of up to 3 months, with savings capped at $100 a month.

The label lists two contraindications: a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a past serious allergic reaction to semaglutide or any ingredient. It is approved only for adults with type 2 diabetes. It is not recommended in severe gastroparesis, and people with diabetic retinopathy should be monitored.

The label doesn't single out one organ. Its less common serious risks include acute pancreatitis, gallbladder disease such as gallstones, acute kidney injury (usually from dehydration after vomiting or diarrhoea) and worsening diabetic retinopathy. The boxed warning covers thyroid C-cell tumours seen in rodents; whether that happens in humans is unknown.

No trial measured time to a fixed number of pounds, and Ozempic is approved for type 2 diabetes, not weight loss; the weight-management brand is Wegovy. In Wegovy's 68-week trials, weight loss built up gradually to an average of 9.6% to 16.0% of body weight. How long 20 lb takes depends on starting weight and individual response.

Nausea, diarrhoea, vomiting and constipation are common, especially while the dose is rising. A boxed warning covers thyroid C-cell tumours seen in rodents, and rarer serious risks include pancreatitis, gallbladder disease and kidney injury. It is also a long-term prescription treatment, and grey-market versions have FDA-documented quality problems.

Semaglutide is sold under the brand names Ozempic, Wegovy and Rybelsus, made by Novo Nordisk. Ozempic is approved for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events (heart attack, stroke, cardiovascular death); the injection is also approved to lower the risk of worsening kidney function, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Wegovy is approved for injection: chronic weight management in adults with obesity or overweight with at least one weight-related condition and in children 12 years and older with obesity, lowering the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic MASH (fatty-liver inflammation) with moderate to advanced liver fibrosis in adults (accelerated approval); tablets: the same weight-management and cardiovascular uses in adults only. Rybelsus is approved for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events in those at high risk.

The generic name for Ozempic is semaglutide. Ozempic is Novo Nordisk's brand, approved for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events (heart attack, stroke, cardiovascular death); the injection is also approved to lower the risk of worsening kidney function, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

The generic name for Wegovy is semaglutide. Wegovy is Novo Nordisk's brand, approved for injection: chronic weight management in adults with obesity or overweight with at least one weight-related condition and in children 12 years and older with obesity, lowering the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic MASH (fatty-liver inflammation) with moderate to advanced liver fibrosis in adults (accelerated approval); tablets: the same weight-management and cardiovascular uses in adults only.

The generic name for Rybelsus is semaglutide. Rybelsus is Novo Nordisk's brand, approved for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events in those at high risk.

Yes. Ozempic is a brand of semaglutide, made by Novo Nordisk: the active ingredient is semaglutide. It comes as a once-weekly injection (multi-dose pen or single-dose prefilled syringe); also once-daily Ozempic tablets, dosed at injection: 0.25 mg once weekly to start, up to 2 mg once weekly; tablets: 1.5 mg once daily to start, up to 9 mg once daily. Compounded or research-vial semaglutide is not Ozempic and has not been through its FDA review.

Yes. Wegovy is a brand of semaglutide, made by Novo Nordisk: the active ingredient is semaglutide. It comes as a once-weekly injection (single-dose pen or syringe, or 4-dose FlexTouch pen; the 7.2 mg pen is sold as Wegovy HD) or once-daily tablet, dosed at injection: 0.25 mg once weekly to start, usually 2.4 mg once weekly, up to 7.2 mg for weight reduction in adults; tablets: 1.5 mg once daily to start, 25 mg once daily maintenance. Compounded or research-vial semaglutide is not Wegovy and has not been through its FDA review.

Yes. Rybelsus is a brand of semaglutide, made by Novo Nordisk: the active ingredient is semaglutide. It comes as a once-daily tablet, dosed at 3 mg once daily for 30 days to start, then 7 mg, up to 14 mg once daily. Compounded or research-vial semaglutide is not Rybelsus and has not been through its FDA review.

Ozempic and Wegovy contain the same active ingredient, semaglutide, and both are made by Novo Nordisk. They are approved for different uses and doses: Ozempic for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events (heart attack, stroke, cardiovascular death); the injection is also approved to lower the risk of worsening kidney function, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (injection: 0.25 mg once weekly to start, up to 2 mg once weekly; tablets: 1.5 mg once daily to start, up to 9 mg once daily); Wegovy for injection: chronic weight management in adults with obesity or overweight with at least one weight-related condition and in children 12 years and older with obesity, lowering the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic MASH (fatty-liver inflammation) with moderate to advanced liver fibrosis in adults (accelerated approval); tablets: the same weight-management and cardiovascular uses in adults only (injection: 0.25 mg once weekly to start, usually 2.4 mg once weekly, up to 7.2 mg for weight reduction in adults; tablets: 1.5 mg once daily to start, 25 mg once daily maintenance).

Ozempic and Rybelsus contain the same active ingredient, semaglutide, and both are made by Novo Nordisk. They are approved for different uses and doses: Ozempic for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events (heart attack, stroke, cardiovascular death); the injection is also approved to lower the risk of worsening kidney function, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (injection: 0.25 mg once weekly to start, up to 2 mg once weekly; tablets: 1.5 mg once daily to start, up to 9 mg once daily); Rybelsus for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events in those at high risk (3 mg once daily for 30 days to start, then 7 mg, up to 14 mg once daily).

Wegovy and Rybelsus contain the same active ingredient, semaglutide, and both are made by Novo Nordisk. They are approved for different uses and doses: Wegovy for injection: chronic weight management in adults with obesity or overweight with at least one weight-related condition and in children 12 years and older with obesity, lowering the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and noncirrhotic MASH (fatty-liver inflammation) with moderate to advanced liver fibrosis in adults (accelerated approval); tablets: the same weight-management and cardiovascular uses in adults only (injection: 0.25 mg once weekly to start, usually 2.4 mg once weekly, up to 7.2 mg for weight reduction in adults; tablets: 1.5 mg once daily to start, 25 mg once daily maintenance); Rybelsus for type 2 diabetes in adults: improving blood-sugar control alongside diet and exercise, and lowering the risk of major cardiovascular events in those at high risk (3 mg once daily for 30 days to start, then 7 mg, up to 14 mg once daily).